Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like another offering to get compliant with the America
Whatever this comment means....
Just look at that price action! The Holy Grail of the medical industry.
Good to know, but, even assuming we get there, it still seems like we are a LONG ways out from commercialization! I'm bullish long term, but short term, who knows? Haven't posted here in probably a couple of years. I sold my position a long time ago and plan to jump back in at some point, but I don't think I'm ready to take the plunge yet.
Know Labs, Inc. - Developing a Non-Invasive Blood Glucose Monitoring
New article on $KNW:
https://www.rfidjournal.com/bio-rfid-measures-blood-glucose-without-pricking-fingers
Know Labs, Inc | Ron Erickson | Benzinga All Access
$KNW
“The completion of Gen 1 brings Know Labs closer to achieving its ultimate goal of delivering the world’s first FDA-cleared non-invasive blood glucose monitor for the billions of people living with diabetes…”
Video showing the making of the Gen 1:
“If somebody were to make a noninvasive glucose sensor that was as accurate as in a watch, IT WOULD BE A MIRACLE… that would be a great outcome for the world. IT WOULD ALSO BE A CATASTROPHIC EVENT, if you will, FOR US.
-Kevin Sayer, CEO Dexcom
The Rise Of Glucose Monitoring Among Non-Diabetics
Completely agree. July being already the 5th anniversary of the public announcement of the tech. I would definitely welcome the monetization sooner than later.
I hope it's a lot sooner than a "few years off". I'm 78 now and have been a believer and investor in this company's tech for 13 years. I know Ron has been a believer and he isn't a spring chicken either.
I don't think it will take that long to start producing revenue. They have the science, the design is done for a small device and they have the manufacturing all set up. I do believe the Uband is a few more years out but the KnowU box seems to be ready to generate some much needed cash. IMO
It is a huge deal. One of the most prestigious clinics in the world has validated the tech. This is probably the best news in 5 years. The real move will be when the final product starts to bring in revenue. A few years off.
I’m here and ecstatic! Official validation from the Mayo Clinic… huge deal.
So, where the heck is everybody. A report (peer reviewd) comes out today That the sensor Know has been working on and developeing is 100% accurate and nobody has any comments. Shouldn't we all be jumping for joy or am I missing somethin?
I'm wondering what type of partnership Know Labs is looking for? Would Know Labs just assume the role of product platform inventor and manufacturer and leave the distribution, sales and marketing to the partner? Such an immense international marketplace is mind boggling.
Wow, 5 years for a prototype. That is far far longer than I evere imagined but even without the FDA approval for the BGL version, this apparatus will be a huge game changer for a lot of different applications. We should soon see a huge increase in our share value (hopefully). I know the company is laser focused on the FDA approval right now but after that gets approved I'm sure they will quickly turn to the other avenues that this device could be used for. Looks like all the hard scientific stuff is behind them now. Let's all rejoice, sit back and enjoy the wild ride ahead..
$KNW
“The sensor…the guts of the Bio-RFID…is complete.”
-Ron Erickson, CEO & Founder
“We have in house all of the componentry necessary to build 100 of the gen 1 prototypes.”
-Pete Conley, Chief Financial Officer & Senior Vice President Intellectual Property (IP)
Great call! Super Bullish.
Key takeaways from earnings call:
-159 patents approved and pending
-23 institutional investors
-Actively seeking partnerships
-Enough cash to last through Feb 2024
-Target MARD < 10%
CEO Ron tweet:
Great detailed thread on the recent advances and developments @TheKnowLabs $KNW. @diabetesdaily @diaTribeNews @JDRFResearch #diabetes https://t.co/zZ81SSB0zh
— Ron Erickson (@ronerickson) May 9, 2023
I got the information from an individual in the know... the KNW team previously indicated that they expected the prototype soon, but I don't think they would/could disclose this milestone until they had the device in hand. Even when they get the first manufactured device I'm sure they will be making modifications before producing the final device that goes to the FDA.
Where did you obtain this news? Curious. Is it something the company has already disclosed? I am sure the update on the 15th should be a good one too.
It sure seems like progress is being made.
$KNW
New page on the Know Labs website - “Research & Validation”
https://www.knowlabs.co/research-and-validation
I'll believe it when I see it
I know this is really good news. This is probably the best news they have delivered. This is a big milestone. I just fear that they will continue to slow walk this whole thing.
Lol let’s hope not.
They're going to continue to refine for 6 more years....
This is what we’ve been waiting for, guy. The results are enough to satisfy the requirements for fda submission but they’re going to continue to refine to make it more accurate.
"We have successfully COMPLETED our foundational studies". Finally, but what's next? 6 years of additional studies???
$KNW In aggregate MARD of 20.6% (the whole). MARD for
Trial 7 9.5%,
Trial 78 10.9%,
Trial 36 12.44%
Trial 40 12.62%
Trial 71 12.78%
Ah hah. This is how data analysis and algorithm refinement works.
" the study resulted in a mean absolute relative difference (MARD) of 20.6% and performed with 46% of predictions within the U.S. Food and Drug Administration’s (FDA) recommended limit for accuracy for new blood glucose monitors."
“Study demonstrates the Bio-RFID™ sensor can deliver stable, repeatable results in predicting blood glucose concentrations using the Dexcom G6® as a reference device. “
https://www.knowlabs.co/post/know-labs-study-validates-technical-feasibility-of-novel-sensor-for-non-invasive-glucose-monitoring?mc_cid=8fc09dabc4&mc_eid=c415307cea
Why rush perfection. Take your time and bring your A game to the table.
The FDA Clinical Trials maybe close at hand. But, as we all have learned, there's no rushing this company to do anything.
The FDA Clinical Trials maybe close at hand. But, as we all have learned, there's no rushing this company to do anything.
The wheels of real progress move very slowly. But, I am happy we finally got the results. I was starting to think I imagined the mayo clinic story.
Got it. Thanks for the reply.
Followers
|
75
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3533
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
About Know Labs, Inc.
Know Labs, Inc. (f/k/a Know Labs Incorporated) is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at http://bit.ly/knowlabs
Overview
Historically, the Company focused on the development of our proprietary ChromaID technology. Using light from low-cost LEDs (light emitting diodes) we map the color of substances, fluids and materials and with our proprietary processes we can authenticate, identify and diagnose based upon the color that is present. The color is both visible to us as humans but also outside of the humanly visible color spectrum in the near infra-red and near ultra-violet and beyond. Our ChromaID scanner sees what we like to call “Nature’s Color Fingerprint.” Everything in nature has a unique color identifier and with ChromaID we can see it, and identify, authenticate and diagnose based upon the color that is present. Our ChromaID scanner is capable of uniquely identifying and authenticating almost any substance or liquid using light to create, record and detect its unique color signature. We will continue to develop and enhance our ChromaID technology and extend its capacity. More recently, we have focused upon extensions and new inventions that are derived from and extend beyond our ChromaID technology. We call this technology Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly in to the commercialization phase of our Company as we work to create revenue generating products for the marketplace.
ChromaID and Bio-RFID: Foundational Platform Technologies
Our ChromaID and Bio-RFID technologies provide a platform upon which a myriad of applications can be developed. As platform technologies, they are analogous to a smartphone, upon which an enormous number of previously unforeseen applications have been developed. ChromaID and Bio-RFID technologies are “enabling” technologies that bring the science of electromagnetic energy to low-cost, real-world commercialization opportunities across multiple industries. The technologies are foundational and, as such, the basis upon which the Company believes a significant business can be built.
As with other foundational technologies, a single application may reach across multiple industries. The ChromaID technology can, for example effectively differentiate and identify different brands of clear vodkas that appear identical to the human eye. By extension, this same technology can identify pure water from water with contaminants present. It can provide real time detection of liquid medicines such as morphine that have been adulterated or compromised. It can detect if jet fuel has water contamination present. It could determine when it is time to change oil in a deep fat fryer. These are but a few of the potential applications of the ChromaID technology based upon extensions of its ability to identify different clear liquids.
Similarly, the Bio-RFID technology can non-invasively identity the presence and quantity of glucose in the human body. By extension, there may be other molecular structures which this same technology can identity in the human body which, over time, the Company will focus upon. They may include the monitoring of drug usage or the presence of illicit drugs. They may also involve identifying hormones and various markers of disease.
The cornerstone of a company with a foundational platform technology is its intellectual property. We have pursued an active intellectual property strategy and have been granted 12 patents. We currently have 20 patents pending. We possess all right, title and interest to the issued patents.
About Our Team
Phil Bosua
Chief Executive Officer
Phil Bosua is an internationally recognized inventor and innovator. His expertise in lighting lead him to found LIFX (www.lifx.com) where he created the world’s first commercial smart light bulb. The 2012 crowdsourcing launch of his smart light bulb raised $1.3 million in six days and attracted $12 million in funding from Sequoia Capital (www.sequoiacap.com). This groundbreaking invention earned him the prestigious Edison Gold Award (www.edisonawards.com) presented by Elon Musk to innovators who create products that have a positive impact on the world. Bosua also founded RAAI, Inc., where he continued his innovative creation of new uses of light. Bosua said, “The time I have spent in the Visualant lab working on advancing their technology has been some of the most scintillating moments of my career. Ron Erickson and Visualant have provided support to allow me and the lab team to explore new products and discover new technologies. I’m excited by the technology platform we are creating, knowing that it will benefit millions of people around the world and be equally as good for our shareholders.”
LinkedIn: http://bit.ly/2yeBNR9
Press Release: http://bit.ly/2HJRZsJ
Ronald P. Erickson
CFO, President and Chairman of the Board.
Mr. Erickson has been a director and officer of the Company since April 24, 2003. He currently serves as the Company's Chairman, Chief Executive Officer and President. He was appointed to the positions of CEO and President on November 10, 2009. Earlier, he was appointed President and Chief Executive Officer of the Company on September 29, 2003, and resigned from this position on August 31, 2004 at which time he was appointed Chairman of the Board. A seasoned executive with more than 30 years of experience in the high technology, telecommunications, micro-computer, and digital media industries, Mr. Erickson was the founder of Know Labs. In addition to his Know Labs responsibilities he also serves as Chairman of ivi, Inc. a streaming media company and eCharge Corporation an Internet based transaction processing company. He is formerly Chairman, CEO and Co-Founder of Blue Frog Media, a mobile media and entertainment company; Chairman, CEO and Co-founder of GlobalTel Resources, a provider of telecommunications services; Chairman, Interim President and CEO of Egghead Software, Inc. the large software reseller where he was an original investor; Chairman and CEO of NBI, Inc.; and Co-founder of MicroRim, Inc. the database software developer. Earlier, Mr. Erickson practiced law in Seattle and worked in public policy in Washington, DC and New York, NY. Additionally, Mr. Erickson has been an angel investor and board member of a number of public and private technology companies. Mr. Erickson has a BA from Central Washington University, a MA from the University of Wyoming and a JD from the University of California, Davis. He is licensed to practice law in the State of Washington and the District of Columbia.
LinkedIn: http://bit.ly/2t2oE7T
Bill Owens
Know Labs Board of Directors
Admiral Owens is currently the co-founder and executive chairman of Red Bison Advisory Group, a company which identifies opportunities with proven enterprises in China, the Middle East, and the United States and creates dynamic partnerships focusing on: natural resources (oil, gas and fertilizer plants), real estate, and information and communication technology. Most recently, he was the chairman of the board of CenturyLink Telecom, the third largest telecommunications company in the United States and was on the advisory board of SAP USA. Owens serves on the board of directors at Wipro Technologies and is a director of the following private companies: Humm Kombucha, a beverage company and Versium. Owens is on the advisory board of the following private companies: Healthmine, Platform Science, Sarcos, Sierra Nevada Corporation, and Vodi. Owens is on the board of trustees at EastWest Institute, Seattle University, and an advisor to the Fiscal Responsibility Amendment (CFFRA) Association which aims to establish a balanced budget amendment to the US Constitution. He is also a member of the Council of Foreign Relations.
LinkedIn: http://bit.ly/2K6DJwx
Press Release: http://bit.ly/2JzG7PO
CONTACT US
Know Labs, Inc.
Jordyn Theisen, Ph. 206-903-1351
Email: jordyn@knowlabs.co
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/KNWN/company-info
Ticker: $KNWN
OTC Market Tier: OTCQB
CIK code: 0001074828
Company name: Know Labs, Inc.
Company website: http://bit.ly/knowlabs
Incorporated In: NV, USA
##### recent news/filings
Latest filings: http://www.otcmarkets.com/stock/KNWN/filings
Latest financials: http://www.otcmarkets.com/stock/KNWN/financials
Latest news: http://www.otcmarkets.com/stock/KNWN/news - http://finance.yahoo.com/q/h?s=KNWN+Headlines
Corporation WIKI:
Corporate website internet archive: http://bit.ly/knowlabs
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |